Bipolar disorder treatment review published
Analysis based on 10 articles · First reported Aug 11, 2026 · Last updated Aug 26, 2026
The publication may influence clinical prescribing patterns for bipolar disorder, potentially benefiting pharmaceutical companies whose drugs are identified as effective. However, the direct market impact is limited as the review does not introduce new treatments but consolidates existing evidence.
An international research team led by The Ottawa Hospital, in collaboration with the University of Barcelona, University of Padua, Paris Nanterre University, and University of Southampton, published a comprehensive living umbrella review in The BMJ identifying the most effective treatments for bipolar disorder across age groups and mood phases. The review analyzed 77 meta-analyses covering 116 treatments and resulted in the creation of the EBI-BD open-access web platform, which presents treatment efficacy, side effects, and evidence strength. The findings have been used to update guidelines from the International Society for Bipolar Disorders and the Canadian Network for Mood and Anxiety Treatments. The project was funded by the Canada — Canadian Institutes of Health Research, France — Agence nationale de la recherche, and the United Kingdom — National Institute for Health and Care Research.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard